To exert vest effort to promote health of the people.
SHINPOONG PHARM.CO.,LTD.

News

Title Shin Poong signes the supply agreement of Medicurtain® with Greenpine pharmaceutical.co.ltd in China
Date 2018.02.08 Hit 1697
Attachments

 

 

 

Shin Poong Pharmaceutical (CEO Ryu Jei-Man) had signed an exclusive supply agreement of Medicurtain® with Greenpine pharmaceutical Co., Ltd. in China on the 7th of March, 2018. Key agreements are that Shin Poong will exclusively supply Medicurtain® to Greenpine in China, yet Shin Poong continues to own trademark rights and patents. Total agreement amount is expected to be 10.77 million US dollars for 8 years, with 520 thousand US dollars of loyalty fee.

Medicurtain®, a surgical adhesion barrier developed by Shin Poong’s own technology, is a combination of hyaluronic acid (HA) with biocompatibilities and wound healing effects, and hydroxyethyl starch (HES) with outstanding anti-blood coagulation and anti-inflammatory action, which is developed uniquely as an anti-adhesion barrier injection for post surgeries.


Large-scale clinical trials have shown that not only the function of forming a physical barrier by highly viscoelastic hyaluronic acid, but also excellent anti-adhesion effect by preventing of thrombosis and inflammation, which is the basis of adhesion. Medicurtain® satisfies both surgeons and patients by minimizing the adverse events caused by postoperative adhesion and has the equivalent effect of film type prodcuts and convenience of liquid type products. Currently, Medicurtain® has indications for preventing adhesion formation hysteroscopic, abdominal, spinal, thyroid and nasal/sinus surgeries.


Meanwhile, MediCurtain® won the 'Presidential Award' at Korea Invention Patent Exhibition 2015, and acquired the CE certification of EU in 2012 for the first time in Korea as an anti-adhesion barrier and the ISO 13485 certification, medical device quality systems, the same year.

The novel technology of Medicurtain® has already been patented and registered in the US, Japan, Australia, Canada, China and Europe and is expected to be a global blockbuster product as distributionship negotiations are in progress with many distributors in various countries.


 

 

 

 

Prev Shin Poong exhibites at CPhI Worldwide 2017 in Frankfurt
Next Shin Poong ready to begin exports of malaria drug Pyramax